Tag: Testing

Categories
Health

What the Coronavirus Variants Imply for Testing

What the Coronavirus Variants Mean for Testing

In January 2020, just a few weeks after the first Covid-19 cases appeared in China, the full genome of the new coronavirus was published online. Using this genomic sequence, the scientists developed a wide range of diagnostic tests for the virus.

But the virus has mutated since then. And with the development of the coronavirus, the test landscape has also evolved. The emergence of new variants has generated great interest in the development of tests for certain virus mutations and concerns about the accuracy of some existing tests.

“With this Covid diagnostic, we had a time crisis, we had to get something out of it,” said Lorraine Lillis, scientific program manager at PATH, a global non-profit health organization that has been tracking coronavirus tests. “It usually takes a long time to diagnose and we would normally challenge it with multiple variations.” She added, “And we do it, but we do it in real time.”

The Food and Drug Administration has warned that new mutations in the coronavirus could make some tests less effective. And last week, PATH launched two online dashboards to monitor how certain variants can affect the performance of existing diagnostic tests.

So far, scientists have agreed that there is no evidence that the known worrying variants will cause tests to fail completely. “The tests are working very, very well today,” said Mara Aspinall, an expert in biomedical diagnostics at Arizona State University.

But Manufacturers and regulators need to remain vigilant to keep up with an ever-changing virus, scientists say. When variants elude detection, it can be of concern not only to individual patients who may not receive the treatment they need, but also to public health.

If a test misses someone infected with a variant, that person may not realize that they need to be isolated. “And then that person must not be quarantined, circulated in the community and possibly passed this variant on to others,” said Gary Schoolnik, doctor and infectious disease expert at Stanford University and chief medical officer of Visby Medical, a diagnostics company that does a coronavirus test. “And so, if variants are missing, a diagnostic test can actually promote the spread of this variant.”

Molecular tests, such as the widely used polymerase chain reaction or PCR test, are used to detect specific sequences of the coronavirus genome. If mutations occur in these “target” sequences, the tests may no longer be able to detect the virus, leading to false negative results.

“You could get into a situation where you were unlucky when you decided to take your test and something came up that made your test less effective,” said Nathan Grubaugh, a virologist at Yale University.

The gene for the virus’s signature spike protein, known as the S gene, has been particularly susceptible to mutation, and tests targeting this gene may miss certain variants. For example, Thermo Fisher’s TaqPath test fails to detect the mutated S gene of the B.1.1.7 variant, which was first identified in the UK and is now rapidly spreading in the US.

However, the test is not only based on the S gene. It has three goals, yet it can still provide accurate results by detecting two more sections of the coronavirus genome.

Only 1.3 percent of molecular tests are based solely on an S-gene target. This is based on calculations made by Rachel West, a postdoctoral fellow at the Johns Hopkins Center for Health Security. The rest either target more stable regions of the genome that are less likely to mutate, or have multiple target sequences, making them less prone to failure. “It is very unlikely that you will get mutations in all,” said Dr. Lillis.

Updated

April 14, 2021, 9:50 p.m. ET

The FDA has listed four different molecular tests “the performance of which could be affected by the variants,” but states that the tests should continue to work. Three of the tests have multiple objectives; A fourth can be a little less sensitive if the virus has a particular mutation and is present in very small amounts. (The four tests are the TaqPath Covid-19 Combo Kit, the Linea Covid-19 Assay Kit, the Xpert Xpress and Xpert Omni SARS-CoV-2, and the Accula SARS-CoV-2 test.)

“We don’t think these four tests are significantly affected,” said Dr. Tim Stenzel, who heads the FDA’s In Vitro Diagnostic and Radiological Health Office. “We published this information out of caution and transparency.”

Antigen tests are less sensitive than molecular tests, but they are usually cheaper and faster and are widely used in coronavirus screening programs. These tests detect specific proteins on the outside of the virus. Some genetic mutations could alter the structure of these proteins and allow them to evade detection.

Most antigen tests target the nucleocapsid protein. The gene that codes for this protein, known as the N gene, is more stable and mutated than the S gene, and the FDA has not listed any antigen tests as of concern. “We didn’t find any that hoisted a red flag, nor have we received any reports,” said Dr. Stenzel.

However, experts note that not every test maker discloses the specific sequences their tests target and the virus continues to mutate. “There is no evidence that any particular molecular assay, or even an antigen test, completely misses the boat for detection.” said Neha Agarwal, the assistant director of diagnostics at PATH. “But things will change.”

The FDA continues to monitor the situation and weekly reviews the coronavirus sequence databases to see if the virus is developing in a way that may help avoid diagnostic tests. “We are very vigilant,” said Dr. Stenzel. “And we will stay vigilant.”

As the variants spread, researchers are also working to develop and improve tests to detect them. At the moment, identifying a variant is typically a two-step process. First, a standard coronavirus test, such as a PCR test, is used to determine if the virus is present. If the test is positive, a sample will be sent for genomic sequencing.

“These two tasks are currently performed in two separate workflows,” said Juan Carlos Izpisua Belmonte, developmental biologist at the Salk Institute in La Jolla, California. “This means more time, work and resources.”

Many researchers are currently working on integrated solutions – tests that can be used to determine if someone is infected with the virus and whether they may have a particular variant.

For example, Dr. Izpisua Belmonte and colleague Mo Li, a stem cell biologist at King Abdullah University of Science and Technology in Saudi Arabia, described a new test method that can be identified in a recent article Mutations in up to five different regions of the coronavirus genome.

And Dr. Grubaugh and his colleagues have developed a PCR test that can be used to detect certain combinations of mutations that characterize three questionable variants: B.1.1.7; B.1,351, which was first discovered in South Africa; and P.1, first found in Brazil. (The work has not yet been published in a scientific journal.)

Dr. Grubaugh said researchers in Brazil, South Africa and elsewhere are already using the tests to sift through a mountain of coronavirus samples and identify those that should be prioritized for full genomic sequencing. “The main interest of our group is to improve genomic surveillance through sequencing, especially in areas with limited resources,” said Dr. Grubaugh. “If you want to know if there are variants, you need a way of triage.”

A number of companies are also starting to publish coronavirus tests that they say can differentiate between certain variants, although these are for research purposes only. It is “infinitely more difficult” to create a test that can definitely diagnose someone with a particular variant, said Dr. Grubaugh.

Similar mutations come in different variants, making it difficult to differentiate between them. The mutations of interest change with the virus, and sequencing remains the best way to get a complete picture of the virus.

But tests that can look for specific mutations could be an important public health tool, Ms. Agarwal said: “These newer diagnoses that examine the variants will be really crucial to understanding the epidemiology of the virus and I think our next generation plan the efforts against it. “

Categories
Health

U.S. begins testing Moderna’s Covid vaccine booster photographs for variant from South Africa

U.S. begins testing Moderna's Covid vaccine booster shots for variant from South Africa

A nurse draws a vaccine for Moderna Coronavirus Disease (COVID-19) on March 5, 2021 at the East Valley Community Health Center in La Puente, California.

Lucy Nicholson | Reuters

The National Institutes of Health have started testing a new coronavirus vaccine from Moderna, which is designed to protect against a problematic variant first found in South Africa, the agency said on Wednesday.

According to the agency, the phase 1 study, which is led and funded by the National Institute for Allergies and Infectious Diseases of the NIH, will test how safe and effective the new shot is against the variant known as B.1.351 in around 210 healthy adults .

The study, which has already had some of the first vaccinations, will include approximately 60 adults who participated in Moderna’s original Covid-19 vaccine studies last year, as well as approximately 150 people who have not yet received a Covid-19 vaccine at one Statement.

Returning participants, who were given two syringes of the original vaccine 28 days apart at different doses early last year, will split up.

Some of them get a single booster shot with the new vaccine at a higher dose while others get the new vaccine at a lower dose, the statement said. Remaining participants will be offered a booster shot with the original vaccine “as part of a separate clinical trial protocol”.

Researchers will take blood samples from participants throughout the study, which can be tested against other circulating strains of the virus to see if the vaccine elicits an immune response.

The study will recruit volunteers in the Atlanta, Cincinnati, Seattle and Nashville, Tennessee areas and should be fully enrolled by the end of April, the agency said.

Variant B.1.351, first discovered in South Africa at the end of last year, has given scientists more cause for concern compared to other variants. The variant appears to spread more easily than the original “wild-type” strains, and research shows that it may evade some of the safeguards created by therapeutics and vaccines.

So far, 312 Covid-19 cases with variant B.1.351 have been identified in the United States, according to the latest data from the Centers for Disease Control and Prevention.

“Preliminary data shows that the COVID-19 vaccines currently available in the US should provide adequate protection against SARS-CoV-2 variants,” said NIAID Director and Chief Medical Officer of the White House, Dr. Anthony Fauci, in a statement.

“However, out of caution, NIAID has continued its partnership with Moderna to evaluate this variant vaccine candidate should an updated vaccine be required,” said Fauci.

The US Food and Drug Administration has already announced that it will accelerate the approval process for the updated vaccines, which target the problematic variants, so that no lengthy clinical trials are required.

However, an independent safety monitoring committee will continue to monitor the trials to ensure the shots are safe, the NIH statement said.

Categories
Health

The C.D.C. and N.I.H. launch a fast, at-home testing initiative in Tennessee and North Carolina.

The C.D.C. and N.I.H. launch a rapid, at-home testing initiative in Tennessee and North Carolina.

The Centers for Disease Control and Prevention and the National Institutes of Health announced a new initiative on Wednesday to see if the frequent and widespread use of rapid coronavirus tests is slowing the spread of the virus.

The program will provide free antigen testing at home to everyone in two communities, Pitt County, NC, and Hamilton County, Tennessee, for free, bringing a total of 160,000 people to test for the coronavirus three times a week for a while a month.

“This is exactly what I and others have been calling for almost a year – widespread, accessible, rapid testing to contain transmission,” said Michael Mina, Harvard University epidemiologist who advocated rapid rapid testing at home programs.

He added, “It’s something anyone can do if they take 30 seconds out of the day three times a week to do the test.”

Antigen tests are cheaper and faster than PCR tests, which are the gold standard for diagnosing Covid-19, the disease caused by the virus. However, they are less sensitive and more prone to false negative results. Mathematical models have shown that if these tests are used frequently, they can still reduce the transmission of the virus.

The tests can help identify people who may not realize they are infectious and cause them to self-isolate before they can transmit the virus to others. Real world data is limited, however, and with virus cases still high across the country, testing is still essential, according to public health experts.

“We have all hypothesized that large-scale home testing could stop the chain of transmission of the virus and allow communities to discover many more cases,” said Bruce Tromberg, who heads the National Institute for Biomedical Imaging and Bioengineering and its rapid acceleration directs the diagnostic program that provides the tests for the initiative. “All mathematical models predict that. But this is an example from the real world, real life. “

Residents who choose to participate in the program can have the tests brought to their home or collect them from local distribution locations. An online tool guides participants through the testing process and helps them interpret their results. Residents can also volunteer to take surveys to see if frequent tests have changed their behavior, knowledge of Covid-19, or their minds about vaccination.

Researchers from the University of North Carolina and Duke University will compare the positivity, case, and hospitalization rates in these two communities with those in other similar communities that are not in the program.

A. David Paltiel, Professor of Health Policy and Management at the Yale School of Public Health, described the start of a real-world study of the effectiveness of rapid home screening as “simply good news.” However, he cautioned that the results need to be interpreted carefully, especially if residents who choose to participate in the initiative are not representative of the entire community.

“We know that self-selection tends to bring out the concerned and a disproportionate number of people who are already Covid-aware or Covid-conscientious,” he said.

“It will be great to see how it works when it’s in the hands of people who really care,” he added. However, he said the results may not be broadly applicable to screening programs that require participation, as may be the case with some workplace and school programs.

Categories
Health

Why Coronavirus Testing Nonetheless Issues

Why Coronavirus Testing Still Matters

Last May, the city of Los Angeles turned a fabled baseball park into a mass test site for the coronavirus. In its prime, Dodger Stadium tested 16,000 people for the virus every day, making it the largest testing site in the world, said Dr. Clemens Hong, who oversees coronavirus testing in Los Angeles County.

But in January the city turned and turned the stadium into a huge drive-through vaccination station. Local demand for coronavirus testing has dropped, said Dr. Hong. He said he saw the evidence firsthand recently while visiting a community hospital: “The test site had three people and the vaccination site had a line around the block.”

Los Angeles is not an anomaly. Across the country, attention has largely shifted from testing to vaccination. According to the Johns Hopkins Coronavirus Resource Center, the US is currently running an average of 1.3 million coronavirus tests per day, up from a high of 2 million per day in mid-January.

In some ways, the decline is good news and can be partly attributed to falling case numbers and the increasing pace of vaccination. But the decline is also worrying many public health experts, who find the prevalence of Covid-19 remains stubbornly high. More than 50,000 new cases and 1,000 deaths are counted every day, and only 14 percent of Americans are fully vaccinated.

“We’re very concerned about the resurgence,” said Jennifer Nuzzo, an epidemiologist at Johns Hopkins University. “Everyone was mentally concerned with vaccines. Vaccines are of course very important. But until most of us are protected, testing remains essential. “

The $ 1.9 trillion stimulus package that went into effect this month includes $ 47.8 billion earmarked for testing, tracking and monitoring the virus.

However, with the reopening of society and the spread of vaccines, testing strategies are evolving. Here are four reasons testing is still important, and how officials see the next months and years.

Case numbers remain high and doctors still need to identify people who have contracted the virus so that those people can receive appropriate treatment and care. The gold standard for diagnosing Covid-19 is the polymerase chain reaction or PCR test, which can identify even small traces of genetic material from the coronavirus.

This type of testing will be required while there are Covid-19 cases. However, because the disease is less common, diagnostic tests are less likely to be centralized.

“The game has changed a bit,” said Dr. Hong. “Before, there was just one infection anywhere and we just needed comprehensive access to comprehensive testing. Now we have to be much more focused. “

According to Dr. Hong are shifting diagnostic testing from large, government-run locations to smaller, more dispersed locations that are spread across local communities. Ultimately, if vaccination rates are high enough and cases are low enough, no special testing sites are needed at all. “Then we just get back to the health system,” he said, and coronavirus testing will simply be one of many options on the doctor’s office menu.

Tests are important not only to identify individual patients in need of treatment, but also to public health. If the system works, a timely Covid-19 diagnosis triggers the tracing and quarantine of contacts and can stop the transmission of viruses.

“The vaccine – wonderful, wonderful as it is – is not going to contain this pandemic in and of itself,” he said A. David Paltiel, Professor of Health Policy and Management at the Yale School of Public Health.

Slowing transmission means fewer people will get sick, but it also gives the virus fewer opportunities to mutate. And that reduces the likelihood that dangerous new variants – some of which may potentially evade vaccine-induced immunity – will appear.

If community prevalence is kept low, vaccines can be given “a chance to fight,” said Dr. Paltiel. “The less work we put into the vaccine, the better.”

As schools and offices reopen, routine screening of asymptomatic individuals will help minimize the spread of virus. These screening programs are now starting to run. Many will rely on rapid antigen tests, which are less sensitive than PCR tests but are cheaper and can give results in 15 minutes. (Antigens are molecules like the well-known spike protein that are present on the surface of the coronavirus that stimulate the immune system to produce antibodies.) When used routinely and frequently, antigen tests can be effective in identifying infectious individuals and in several ways Analysis suggests reducing virus transmission.

As vaccination rates increase, these screening programs can become more targeted. If 70 to 80 percent of Americans are vaccinated, the prevalence of Covid-19 is dropping, and there are no outbreaks in groups, it may be possible to simplify comprehensive screening, said Dr. Mary K. Hayden, an Infectious Disease Specialist at Rush University Medical Center in Chicago. “Then, yes, I think we could relax the surveillance tests,” she said before adding.

Frequently asked questions about the new stimulus package

How high are the business stimulus payments in the bill and who is entitled?

The stimulus payments would be $ 1,400 for most recipients. Those who are eligible would also receive an identical payment for each of their children. To qualify for the full $ 1,400, a single person would need an adjusted gross income of $ 75,000 or less. For householders, the adjusted gross income should be $ 112,500 or less, and for married couples filing together, that number should be $ 150,000 or less. To be eligible for a payment, an individual must have a social security number. Continue reading.

What Would the Relief Bill do for Health Insurance?

Buying insurance through the government program known as COBRA would temporarily become much cheaper. Under the Consolidated Omnibus Budget Reconciliation Act, COBRA generally lets someone who loses a job purchase coverage through their previous employer. But it’s expensive: under normal circumstances, a person must pay at least 102 percent of the cost of the premium. Under the Relief Act, the government would pay the full COBRA premium from April 1 to September 30. An individual who qualified for new employer-based health insurance elsewhere before September 30th would lose their eligibility for free coverage. And someone who left a job voluntarily would also be ineligible. Continue reading

What would the child and dependent care tax credit bill change?

This loan, which helps working families offset the cost of looking after children under the age of 13 and other dependents, would be significantly extended for a single year. More people would be eligible and many recipients would get a longer break. The bill would also fully refund the balance, which means you could collect the money as a refund even if your tax bill were zero. “This will be helpful to people on the lower end of the income spectrum,” said Mark Luscombe, chief federal tax analyst at Wolters Kluwer Tax & Accounting. Continue reading.

What changes to the student loan are included in the invoice?

There would be a big one for people who are already in debt. You wouldn’t have to pay income taxes on debt relief if you qualify for loan origination or cancellation – for example, if you’ve been on an income-based repayment plan for the required number of years, if your school cheated on you, or if Congress or the President whisper $ 10,000 debt gone for a large number of people. This would be the case for debts canceled between January 1, 2021 and the end of 2025. Read more.

What would the bill do to help people with housing?

The bill would provide billions of dollars in rental and utility benefits to people who are struggling and at risk of being evicted from their homes. About $ 27 billion would be used for emergency rentals. The vast majority of these would replenish what is known as the Coronavirus Relief Fund created by CARES law and distributed through state, local, and tribal governments, according to the National Low Income Housing Coalition. This is on top of the $ 25 billion provided by the aid package passed in December. In order to receive financial support that could be used for rent, utilities and other housing costs, households would have to meet various conditions. Household income must not exceed 80 percent of area median income, at least one household member must be at risk of homelessness or residential instability, and individuals would have to be due to the pandemic. According to the National Low Income Housing Coalition, assistance could be granted for up to 18 months. Lower-income families who have been unemployed for three months or more would be given priority for support. Continue reading.

Even then, officials may want to do some level of surveillance testing in high-risk environments such as nursing homes or on high-risk individuals such as travelers, she said.

Tests can help public health officials assess whether efforts to end the pandemic are paying off.

“Do we want to know how well vaccines work? We need to test, ”said David O’Connor, a virologist at the University of Wisconsin, Madison. “How do we know if the variants are more contagious? We have to test. How do we know if the vaccines are effective at controlling the variants? We have to test. “

Large screening programs can also help institutes evaluate the effectiveness of their risk reduction strategies. As cases increase, schools and offices may need to change their mask guidelines, enforce greater social distancing, or increase their ventilation rates.

Testing could also help uncover worrying case clusters that may indicate that a community has not yet reached herd immunity and could benefit from a targeted vaccination campaign.

Many experts today believe that the coronavirus will likely never go away completely. But even if the virus continues to circulate in very small amounts, it’s important to keep an eye on it.

“It’s less about stopping the transmission of the disease and more about understanding where the virus is.” Said Dr. Nuzzo. “What are we missing? And, you know, what could be coming down the road? “

The virus will continue to mutate and new genetic variants will emerge. Some amount of continued testing, even years later, could help scientists identify worrying variants early on.

Tests are of course not perfect and can lead to false negative and positive results. However, they provide a critical window into the activity of a pathogen that is too small to be seen.

“We’re going to want to make sure that after vaccination, people don’t gush up in some other unpredictable way that will get us back to where we started,” said Dr. O’Connor.

Categories
World News

The Covid Testing Droop – The New York Occasions

The Covid Testing Slump - The New York Times

A few weeks ago, Citigroup began making Covid-19 test kits available to many of its employees in Chicago and New York at home. Each kit contains a nasal swab, paper strip, and liquid solution, and people get a result in minutes. “It looks a bit like a pregnancy test,” Dr. Lori Zimmerman, Citigroup Medical Director.

The company distributes enough tests for employees to take three times a week, usually on Monday, Wednesday, and Friday mornings. Citigroup will soon expand the program to a further 6,000 employees across the country. The goal, Zimmerman said, is to help people know they have Covid before they can infect colleagues or customers.

This is the kind of ambitious testing program that many medical experts believe should be available across the country. Why? As more Americans receive vaccination shots, the country is still months away from vaccination. In the meantime, extensive testing can help life return to normal – without triggering deadly new Covid outbreaks.

Unfortunately, the US is going in the opposite direction when it comes to testing. The number of daily tests has decreased by 35 percent since mid-January:

“We have to do more,” said Jennifer Nuzzo, an epidemiologist at Johns Hopkins University. “This pandemic is not over yet. We are still at dangerously high levels. “

Tests have declined in part because the health system has focused instead on giving vaccine shots. And vaccinations are indeed more important than Covid tests. But the country shouldn’t have to choose between the two, experts say. If the US can speed up both vaccinations and testing, the gains in terms of lives saved and schools and businesses reopening would be huge.

“It’s paying off,” said Dr. Michael Mina, a Harvard University epidemiologist who has spoken out in favor of more testing. “Tests are one of the easiest and least stressful things we can do.”

For Monica Jurado, a Citi banker on the south side of Chicago, testing has become an easy part of her morning ritual. After a test, she gets ready for work – and 20 minutes later she can see the test result. “It gives me tremendous security to know that I can get to work safely, and so do my employees,” said Jurado.

Several countries around the world, including Australia and South Korea, have already carried out mass tests to stop Covid cases, as Umair Irfan from Vox notes. Many colleges in the United States as well as professional sports leagues have also relied on testing to continue their operations. And Biden administration officials say they are committed to making testing more available, even to people who are not showing symptoms.

“Testing is an important pillar of the president’s strategy,” White House testing coordinator Carole Johnson told me yesterday. “We think it’s really important.”

What does the US need to do more testing?

Money. The recently passed anti-virus law provides $ 50 billion for advanced testing, including $ 10 billion for schools. That will help, say experts, although it’s not yet clear how much.

The tests Citigroup runs cost about $ 5 each when purchased in bulk. A nationwide program of universal mass testing for unvaccinated people would likely cost billions of dollars a week – which, in turn, pales in comparison to the cost of prolonged shutdowns. The country’s current test plan is much less aggressive.

Logistic help. With many hospitals and pharmacies focused on vaccinations, people need places to get tested. The Biden administration is working with state and local officials to open four regional coordination centers in the coming weeks.

Corporate America can also play a role. Large Canadian companies recently formed a consortium to give employees quick score testing, and the group’s organizers announced this week that they are planning to expand into the US

FDA approval. Citigroup was only able to distribute its tests – so-called rapid antigen tests – because it is doing so as part of an academic study. The Food & Drug Administration has not approved the tests used by Citigroup. The agency has approved two more at-home antigen tests, but they are not yet generally available.

One problem is that rapid antigen tests are a little less accurate – some people with Covid are absent – than the other main type of test known as a PCR test, which is not an option for mass testing at home. But that’s fine. Think of it this way: Citigroup recognizes a lot more Covid cases than most employers.

In President Biden’s first two months in office, his administration has made impressive strides in accelerating vaccinations. But he still faces two overwhelming Covid challenges to prevent thousands of unnecessary deaths.

First, he needs to keep speeding up vaccinations – to match the speed at which drug companies are firing shots. (The new goal that Biden announced yesterday – to get 200 million vaccinations in its first 100 days – is not ambitious enough to get there). Second, the administration needs to find a way to reverse the recent decline in testing.

A programming note: I’ll be on break next week and my colleagues will deliver The Morning to your inbox. I’ll be back Tuesday April 6th.

Closed for the time being: “The gasps, the laughter, the whistles, the” Yes, baby! “And the applause”: What New York’s burlesque performers miss.

Modern love: She tried to keep her expectations in check. Would that hurt less?

Lived life: Jessica Walter’s acting career included roles on Broadway and an Emmy-winning twist on the 1970’s Amy Prentiss. But she is perhaps best known as the Martini-sweating matriarch of the Bluth family in Arrested Development. Walter died at the age of 80.

It is hard to imagine a musician having a more intimidating task than completing an unfinished work by Mozart. This is what Timothy Jones, a Mozart expert who teaches at the Royal Academy of Music in London, did to complete fragments of violin sonata that the composer left behind.

Posthumous degrees are not uncommon in classical music. However, Jones’ recent endeavor brings a twist: he made several finished versions of each fragment, each highlighting different aspects of Mozart’s style.

He also benefited from recent research that helped more accurately date Mozart’s compositions. “If I fully understand the context for these fragments, I can ask detailed hypothetical questions about his compositional strategy,” Jones told The Times. “What has he been working on, listening to his compositional interests? That was key because his style was still developing very rapidly until his death in 1791. “

The pangrams from yesterday’s Spelling Bee awakened, awakened and faded. Here is today’s puzzle – or you can play online.

Here’s today’s mini crossword and clue: Enlightened (five letters).

If you feel like playing more, all of our games can be found here.

Thank you for spending part of your morning with The Times. I’ll be gone next week. My co-workers will get to your inbox while I’m away. – David

PS Apoorva Mandavilli, a science reporter for The Times, has a master’s degree in biochemistry, speaks seven languages, and has a thing for Bridgerton. In an interview, she talks about the coverage of the pandemic.

Categories
Health

Pfizer Begins Testing Its Vaccine in Younger Kids

Pfizer Begins Testing Its Vaccine in Young Children

Pfizer has started testing its Covid-19 vaccine in children under the age of 12. This is an important step in reducing the pandemic. The first participants in the study, a pair of 9-year-old twin girls, were vaccinated on Wednesday at Duke University in North Carolina.

Results of the study are expected in the second half of the year, and the company hopes to vaccinate younger children early next year, said Sharon Castillo, a spokeswoman for the drug company.

Moderna is also starting testing its vaccine in children aged six months to 12 years. Both companies have tested their vaccines in children 12 years and older and expect these results in the next few weeks.

AstraZeneca began testing its vaccine in children six months and older last month. Johnson & Johnson has announced plans to extend the vaccine trials to young children after assessing performance in older children.

Immunizing children will help schools reopen and end the pandemic, said Dr. Emily Erbelding, an infectious disease doctor at the National Institutes of Health who oversees the testing of Covid-19 vaccines in specific populations.

An estimated 80 percent of the population may need to be vaccinated for the United States to achieve herd immunity, the threshold above which the coronavirus can no longer infect people. Some adults may refuse to be vaccinated, while others may not produce a robust immune response.

Children under the age of 18 make up about 23 percent of the US population. Even if the vast majority of adults choose vaccines, “herd immunity may be difficult to achieve without vaccinating children,” said Dr. Erbelding.

Pfizer originally announced that it would wait for data from older children before starting trials of its vaccine in children under the age of 12. “We were encouraged, however, by the data from the group of 12-15 year olds,” said Ms. Castillo, who did not elaborate on results so far.

Scientists will test three doses of the Pfizer vaccine – 10, 20, and 30 micrograms – in 144 children. Each dose is assessed first in children aged 5 to 11 years, then in children aged 2 to 4 years, and finally in the youngest group aged six months to 2 years.

After determining the most effective dose, the company will test the vaccine on 4,500 children. Approximately two-thirds of the participants are randomly selected to receive two doses 21 days apart. The remainder received two placebo injections of saline solution. The researchers will study the children’s immune response in blood drawn seven days after the second dose.

Updated

March 25, 2021, 2:39 p.m. ET

“It sounds like a good plan, and it’s exciting to see another Covid-19 vaccine drive studies in children,” said Dr. Kristin Oliver, pediatrician and vaccine expert at Mount Sinai Hospital in New York.

Dr. Oliver said that about half of the parents she sees in the office eagerly await vaccines and even volunteer their children for clinical trials, while the rest are skeptical because comparatively few children get seriously ill with coronavirus infection .

Both parent groups will benefit from knowing exactly how safe and effective the vaccines are in children, she said.

Children make up 13 percent of all reported cases in the United States. More than 3.3 million children tested positive for the virus, at least 13,000 were hospitalized and at least 260 died, noted Dr. Yvonne Maldonado, who represents the American Academy of Pediatrics on the Federal Advisory Board on Immunization Practices.

The figures do not fully capture the damage to the health of children. “We don’t know how a Covid infection will affect the long term,” said Dr. Maldonado.

Other vaccines have helped fight many terrible teething problems that can cause long-term complications. She added, “For some of us who have seen this, we don’t want to go back to that time.”

Children are often more responsive to vaccines than adults, and infants and young children in particular can have a high fever. All side effects are likely to appear soon after the shot, within the first week, and certainly within the first few weeks, experts have said.

Some vaccines are only tested on animals before being studied in children and must be carefully monitored for side effects.

“But that’s a little different because we’ve already had tens of millions of people with these vaccines,” said Dr. Maldonado. “So there is more confidence to give this vaccine to children.”

Some experts suggested that the Food and Drug Administration may need up to six months of safety data from studies in children before the Covid-19 vaccines are approved. However, a spokeswoman said the agency did not expect safety data to support approval of the vaccines for six months.

The Pfizer BioNTech vaccine is approved for children ages 16-18, and approval for that age group was based on just two months of safety data, she said.

Parents will want to know how the companies and the FDA plan to monitor and disclose the side effects of the vaccines and how long they will pursue study participants after the vaccines are approved, said Dr. Oliver.

“I think everyone has learned that,” she said. “The more transparent you can be, the better.”

Categories
Health

Pfizer begins early stage scientific trial testing oral antiviral drug

Pfizer begins early stage clinical trial testing oral antiviral drug

Pfizer said Tuesday it had started an early clinical trial of an experimental oral antiviral drug for Covid-19.

The New York-based company announced that the Phase 1 study of the drug PF-07321332 will be conducted in the United States. The drug belongs to a class of drugs called protease inhibitors, and it works by blocking an enzyme that the virus needs to replicate in human cells.

Protease inhibitors are used to treat other viral pathogens such as HIV and hepatitis C.

“Fighting the COVID-19 pandemic requires both preventive vaccination and targeted treatment of those who become infected with the virus,” Pfizer’s chief scientist Mikael Dolsten said in a press release. “Given the way SARS-CoV-2 is mutating and the ongoing global impact of COVID-19, it is likely that access to therapeutic options will be critical both now and after the pandemic.”

The study comes as Pfizer is also working on an intravenously administered protease inhibitor known as PF-07304814. This drug is currently in a Phase 1b clinical trial in patients hospitalized with Covid-19.

A person walks past the Pfizer building in New York City on March 2, 2021.

Carlo Allegri | Reuters

Pfizer already has an approved vaccine in the US with German drug maker BioNTech, but health experts say the world will need a slew of drugs and vaccines to end the pandemic that is infecting more than 29.8 million Americans and is coming soon Has killed at least 542,991 people over a year, according to the Johns Hopkins University.

Preclinical studies have shown that the oral drug, the first orally ingested protease inhibitor for Covid-19 to be studied in clinical trials, has “strong” antiviral activity against the virus.

Because the drug is taken orally, it can be used outside of hospitals for people newly infected with the virus. The researchers hope the drugs will prevent the disease from getting worse and keep people out of the hospital.

Pfizer said it will provide more details on the drug at the Spring American Chemical Society meeting on April 6.

Categories
Health

Moderna Begins Testing Its Covid Vaccine in Infants and Younger Kids

Moderna Starts Testing Its Covid Vaccine in Babies and Young Children

The pharmaceutical company Moderna has started a study testing its Covid vaccine in children under the age of 12, including babies as young as six months, the company said Tuesday.

The study is expected to enroll 6,750 healthy children in the United States and Canada. According to a spokeswoman, Colleen Hussey, Moderna declined to say how many had signed up or received their first recordings.

“There is a great demand for information about vaccination in children and how it works,” said Dr. David Wohl, the medical director of the University of North Carolina Vaccination Clinic, who is not involved in the study.

In a separate study, Moderna is testing its vaccine in 3,000 children ages 12-17 and could have results for that age group by summer. The vaccine would then have to be approved for use in children so that it would not be immediately available.

Many parents want protection for their children, and vaccinating children should help create the herd immunity that is believed to be critical to ending the pandemic. The American Academy of Pediatrics has called for vaccine studies to be expanded to include children.

Vaccine side effects like fever, sore arms, fatigue, and sore joints and muscles can be more intense in children than adults, and doctors say it’s important that parents know what to expect after their children are vaccinated.

Every child in Moderna’s study receives two recordings 28 days apart. The study will consist of two parts. In the first case, children aged 2 to under 12 can receive two doses of 50 or 100 micrograms each. People under the age of 2 may receive two exposures of 25, 50, or 100 micrograms.

Updated

March 21, 2021, 2:25 p.m. ET

In each group, the first children to be vaccinated are given the lowest doses and monitored for reactions before later participants are given higher doses.

Researchers then do an interim analysis to determine which dose is safest and most likely protective for each age group.

Children in Part 2 of the study receive the doses or placebo shots selected by the analysis, which consist of salt water.

Moderna developed its vaccine in collaboration with the National Institute for Allergies and Infectious Diseases. The company and the institute are working together with the Federal Agency for Biomedical Research and Development on the study.

The children will be followed for a year to look for side effects and measure antibody levels, which will allow researchers to determine whether the vaccine appears to offer protection. Antibody levels will be the main indicator, but researchers will also look for coronavirus infections with or without symptoms.

Dr. Wohl said the study was well designed and likely efficient, but asked why the children should only be observed for one year when adults in Moderna’s study were observed for two years. He also said he was a bit surprised that the vaccine was being tested in children so young so soon.

“Should we first learn what happens to the older children before we go to the really young children?” Asked Dr. Well. Most young children don’t get very sick from Covid, although some develop severe inflammatory syndrome that can be life-threatening.

Johnson & Johnson has also announced that it will test its coronavirus vaccine in babies and toddlers after first testing it in older children.

Pfizer-BioNTech is testing its vaccine in children ages 12-15 and plans to switch to younger groups. The product is already approved for use in the USA from the age of 16.

Last month, AstraZeneca began testing its vaccine in the UK in children 6 years and older.

Categories
Business

Bringing Rigorous Testing to Well being Care Coverage

Bringing Rigorous Testing to Health Care Policy

This assessment method is reminiscent of the traditional approach to assessing new surgical techniques that, after more rigorous testing, have sometimes proven worthless or worse. For example, radical mastectomies were used extensively for decades before randomized trials showed that a much less extensive and disfiguring surgery followed by radiation was an equally effective treatment.

Of course, conducting randomized trials can pose greater challenges to evaluating a new surgery than evaluating a new drug. It can be more difficult to standardize a surgical technique enough to test it on a broad population, and it can be far more difficult to blind the patient for whom he is receiving treatment.

However, such feasibility problems do not apply to new payment methods, which are well-defined and standardized interventions and where it is not desirable to blind medical providers for the payment rules.

However, as in medicine, not all public interventions can or should have randomized ratings. Unique government projects – like the Big Dig in Boston or the Superconducting Super Collider in Texas – have no natural comparison group, either randomly or otherwise. In times of crisis or when political disagreements are more about ideology than impact, the assessment itself can be ill-advised.

However, if – as is so often the case – there is the possibility of a prospective assessment and the law prescribes it, the experience of the innovation center underscores the value and feasibility of randomized socio-political studies. Often times, they can be conducted at the same speed and cost as any prospective study and produce more compelling results. A random assignment, where the government uses a lottery to choose who can receive the program, may also be the fairest way to assign intervention on a limited basis.

Randomized testing may not yet be the standard for government assessment, but such things take time. For example, the Food and Drug Administration was given authority in 1962 to obtain “substantial evidence” of the safety and effectiveness of a new drug. However, it took more than five years for the agency to accept randomized trials as an appropriate standard.

Now that the Biden government correctly reiterates that all federal agencies must make “evidence-based decisions” based on the highest scientific standards, really tough social policy testing may become as natural as it is with new vaccines. This would help ensure that government services are provided as effectively and efficiently as possible.

Amy Finkelstein is John and Jennie S. MacDonald, professor of economics at MIT. She is co-director of J-PAL North America, a research center at MIT that conducts randomized assessments.

Categories
Politics

White Home to Spend Billions to Improve Virus Testing and Ease Reopening

White House to Spend Billions to Increase Virus Testing and Ease Reopening

WASHINGTON – Die Regierung von Biden, die versucht, eine Verzögerung bei den Coronavirus-Tests zu beheben, die die Wiedereröffnung von Schulen und Wirtschaft behindert, sagte am Mittwoch, dass sie 10 Milliarden US-Dollar investieren würde, um das Screening von Schülern und Pädagogen zu beschleunigen, mit dem Ziel, persönlich zurückzukehren Lernen bis zum Ende des Schuljahres.

Der Kongress genehmigte die 10-Milliarden-Dollar-Ausgaben, als er Präsident Bidens 1,9-Billionen-Dollar-Konjunkturpaket verabschiedete, das er letzte Woche gesetzlich unterzeichnet hatte. Die Zentren für die Kontrolle und Prävention von Krankheiten werden das Geld Anfang April an die Staaten verteilen und zusätzliche 2,25 Milliarden US-Dollar ausgeben, um die Tests in unterversorgten Gemeinden außerhalb der Schulen auszuweiten.

Inwieweit diese Schritte zur Wiedereröffnung von Schulen und zur Wiederbelebung der Wirtschaft führen werden, ist unklar. Experten sagen, dass die Vereinigten Staaten nicht annähernd genug Schnelltests haben, um die Art von Routine-Screening durchzuführen, die die Verwaltung vorsieht, damit Schüler und Lehrer sicher in den Unterricht zurückkehren können.

“Dies wird die Nadel nicht bewegen”, sagte Michael Mina, ein Immunologe und Epidemiologe in Harvard, der argumentierte, dass belastende Vorschriften der Food and Drug Administration die Coronavirus-Krise verschärfen, indem sie verhindern, dass neue Arten von Antigen-Schnelltests zugelassen werden.

“Die Staaten brauchen nicht nur Geld”, sagte Dr. Mina. “Die Staaten brauchen nicht nur Rat von der CDC. Die Staaten brauchen den Test, um verfügbar zu sein.”

Die Schritte kommen, da die Coronavirus-Tests landesweit zurückgehen, ein Trend, der die Experten des öffentlichen Gesundheitswesens zutiefst betrifft. Einige Staaten haben Massenteststellen in Massenimpfzentren umgewandelt, und ihre überforderten Gesundheitsabteilungen verfügen nicht über die Bandbreite, um beides zu tun.

Zwischen dem 1. Februar und dem 15. März, als die Infektionsrate sank und sich die Amerikaner auf die Impfung konzentrierten, sank die durchschnittliche Anzahl der täglich durchgeführten Coronavirus-Tests laut Statistiken der Johns Hopkins University um 24 Prozent.

Jennifer B. Nuzzo, eine Epidemiologin von Johns Hopkins, die in einem Interview in der New York Times über den Rückgang eines Meinungsbeitrags schrieb, sagte in einem Interview, dass aggressive Tests für die Beendigung der Pandemie weiterhin von entscheidender Bedeutung seien, insbesondere da ansteckendere Coronavirus-Varianten auftauchten und Staaten ihre Sperrung lockerten Maße. Sie sagte, die Biden-Administration müsse schnell testen, um etwas zu bewirken.

“Ich verstehe, warum sich Staaten auf Impfstoffe konzentrieren”, sagte Dr. Nuzzo. “Es ist sehr wichtig, dass wir der Einführung von Impfstoffen Priorität einräumen, jedoch nicht auf Kosten der Tests.”

Experten wie Dr. Nuzzo und Dr. Mina sagen, dass die USA Tests nie vollständig als wirksames Instrument zur Verfolgung und Eindämmung des Virus eingesetzt haben. Die neuen Initiativen der Biden-Regierung sind ein Versuch, dies zu tun, indem asymptomatische Personen – insbesondere Schüler, Lehrer und Schulpersonal – getestet werden, um Ausbrüche zu erkennen, bevor sie explodieren, anstatt nur diejenigen mit Symptomen zu testen, um festzustellen, ob sie infiziert sind.

Die Wiedereröffnung von Schulen war eine der Hauptprioritäten von Herrn Biden – und eines der umstrittensten Themen, mit denen die Verwaltung konfrontiert ist. Da Millionen amerikanischer Kinder immer noch auf virtuelles Lernen beschränkt sind, sagen Bildungsexperten, dass viele sowohl psychisch als auch akademisch leiden.

Trotzdem arbeiten viele Schulen bereits zumindest teilweise persönlich, und es gibt Hinweise darauf, dass sie dies relativ sicher tun. Untersuchungen zeigen, dass die Verbreitung in der Schule durch einfache Sicherheitsmaßnahmen wie Maskieren, Distanzieren, Händewaschen und Öffnen von Fenstern verringert werden kann.

Der Bildungssekretär von Herrn Biden, Miguel A. Cardona, sagte am Mittwoch, dass die Abteilung nächste Woche einen „nationalen Wiedereröffnungsgipfel für Schulen“ veranstalten und „Best Practices aus dem ganzen Land darlegen werde, wie dies sicher und wie dies zu tun ist schnell.”

Herr Biden, der ursprünglich die Wiedereröffnung aller Schulen innerhalb von 100 Tagen nach seiner Eröffnung forderte, beschränkte dieses Ziel später auf Grund- und Mittelschulen und setzte den Maßstab für die Wiedereröffnung bei „der Mehrheit der Schulen“ oder 51 Prozent. Es gibt jedoch noch viele Hürden, einschließlich der Überzeugung der Lehrergewerkschaften, dass Richtlinien vorhanden sind, um eine sichere Rückkehr zu gewährleisten und die Ängste und Frustrationen der Eltern zu lindern.

Ein Stolperstein für die Wiedereröffnung war die Empfehlung der CDC, dass die Menschen sechs Fuß voneinander entfernt bleiben sollten, wenn sie nicht im selben Haushalt leben. Angesichts des wachsenden Verständnisses der Ausbreitung des Virus fordern einige Experten des öffentlichen Gesundheitswesens die Behörde auf, den empfohlenen Abstand von sechs Fuß auf drei Fuß zu verringern.

Dr. Anthony S. Fauci, der leitende medizinische Berater von Herrn Biden für die Pandemie, und Dr. Rochelle Walensky, die CDC-Direktorin, haben erklärt, dass die Leitlinien für soziale Distanzierung in Schulen derzeit überprüft werden.

Die Regierung teilte am Mittwoch mit, dass die CDC sowie die staatlichen und lokalen Gesundheitsämter den Staaten und Schulen helfen würden, Testprogramme einzurichten. Die CDC aktualisierte auch ihre Leitlinien dazu, welche Arten von Tests in verschiedenen Umgebungen wie Schulen, Gefängnissen oder Pflegeheimen angewendet werden sollten.

Die neuen Leitlinien enthalten weitere Informationen zu verschiedenen Arten von Tests, einschließlich der Auswahl und Interpretation der Ergebnisse. Die Agentur empfiehlt Personen mit Covid-19-Symptomen oder Personen, die möglicherweise einer Krankheit ausgesetzt waren, einen diagnostischen Test durchzuführen.

Diese Tests umfassen Polymerasekettenreaktions- oder PCR-Tests, die sehr kleine Spuren viraler DNA nachweisen können, aber typischerweise in einem Labor verarbeitet werden müssen, und Antigentests, die weniger empfindlich, aber im Allgemeinen billiger und schneller sind.

Antigentests können besonders nützlich sein, um eine große Anzahl von Personen zu untersuchen – beispielsweise in Schulen oder am Arbeitsplatz -, die keine Symptome haben. Aufgrund ihrer geringeren Empfindlichkeit können jedoch nachfolgende Laboruntersuchungen erforderlich sein, so die CDC-Leitlinien.

Häufig gestellte Fragen zum neuen Stimulus-Paket

Wie hoch sind die Konjunkturzahlungen in der Rechnung und wer ist berechtigt?

Die Konjunkturzahlungen würden für die meisten Empfänger 1.400 USD betragen. Diejenigen, die berechtigt sind, würden auch eine identische Zahlung für jedes ihrer Kinder erhalten. Um sich für die vollen 1.400 USD zu qualifizieren, würde eine einzelne Person ein bereinigtes Bruttoeinkommen von 75.000 USD oder weniger benötigen. Für Haushaltsvorstände müsste das bereinigte Bruttoeinkommen 112.500 USD oder weniger betragen, und für Ehepaare, die gemeinsam einreichen, müsste diese Zahl 150.000 USD oder weniger betragen. Um Anspruch auf eine Zahlung zu haben, muss eine Person eine Sozialversicherungsnummer haben. Weiterlesen.

Was würde die Entlastungsrechnung für die Krankenversicherung tun?

Der Kauf einer Versicherung über das als COBRA bekannte Regierungsprogramm würde vorübergehend viel billiger werden. COBRA lässt im Rahmen des Consolidated Omnibus Budget Reconciliation Act im Allgemeinen jemanden, der einen Job verliert, über den früheren Arbeitgeber eine Deckung kaufen. Aber es ist teuer: Unter normalen Umständen muss eine Person mindestens 102 Prozent der Kosten der Prämie bezahlen. Im Rahmen des Hilfsgesetzes würde die Regierung vom 1. April bis 30. September die gesamte COBRA-Prämie zahlen. Eine Person, die sich vor dem 30. September an einem anderen Ort für eine neue arbeitgeberbasierte Krankenversicherung qualifiziert hat, würde die Berechtigung für die kostenlose Deckung verlieren. Und jemand, der freiwillig einen Job verlassen hat, wäre ebenfalls nicht förderfähig. Weiterlesen

Was würde die Rechnung über die Steuergutschrift für Kinder und abhängige Pflege ändern?

Dieser Kredit, der berufstätigen Familien hilft, die Kosten für die Betreuung von Kindern unter 13 Jahren und anderen abhängigen Personen auszugleichen, würde für ein einziges Jahr erheblich verlängert. Mehr Menschen wären berechtigt, und viele Empfänger würden eine größere Pause bekommen. Die Rechnung würde auch das Guthaben vollständig zurückerstatten, was bedeutet, dass Sie das Geld als Rückerstattung einziehen könnten, selbst wenn Ihre Steuerrechnung Null wäre. “Das wird für Menschen am unteren Ende der Einkommensskala hilfreich sein”, sagte Mark Luscombe, Hauptsteueranalyst des Bundes bei Wolters Kluwer Tax & Accounting. Weiterlesen.

Welche Änderungen des Studentendarlehens sind in der Rechnung enthalten?

Es würde eine große für Leute geben, die bereits Schulden haben. Sie müssten keine Einkommenssteuern auf Schuldenerlass zahlen, wenn Sie sich für die Kreditvergabe oder -stornierung qualifizieren – zum Beispiel, wenn Sie für die erforderliche Anzahl von Jahren in einem einkommensabhängigen Rückzahlungsplan waren, wenn Ihre Schule Sie betrogen hat oder wenn Der Kongress oder der Präsident wischen 10.000 Dollar Schulden für eine große Anzahl von Menschen weg. Dies wäre der Fall bei Schulden, die zwischen dem 1. Januar 2021 und Ende 2025 erlassen wurden. Lesen Sie mehr.

Was würde die Rechnung tun, um Menschen mit Wohnraum zu helfen?

Die Rechnung würde Menschen, die Probleme haben und in Gefahr sind, aus ihren Häusern vertrieben zu werden, Milliarden von Dollar an Miet- und Versorgungsleistungen zur Verfügung stellen. Etwa 27 Milliarden US-Dollar würden für die Notfallvermietung verwendet. Die überwiegende Mehrheit davon würde den sogenannten Coronavirus Relief Fund auffüllen, der durch das CARES-Gesetz geschaffen und nach Angaben der National Low Income Housing Coalition über staatliche, lokale und Stammesregierungen verteilt wird. Dies kommt zu den 25 Milliarden US-Dollar hinzu, die durch das im Dezember verabschiedete Hilfspaket bereitgestellt werden. Um finanzielle Unterstützung zu erhalten, die für Miete, Versorgung und andere Wohnkosten verwendet werden könnte, müssten die Haushalte verschiedene Bedingungen erfüllen. Das Haushaltseinkommen darf 80 Prozent des Gebietsmedianeinkommens nicht überschreiten, mindestens ein Haushaltsmitglied muss einem Risiko für Obdachlosigkeit oder Wohninstabilität ausgesetzt sein, und Einzelpersonen müssten aufgrund der Pandemie. Nach Angaben der National Low Income Housing Coalition könnte die Unterstützung bis zu 18 Monate lang gewährt werden. Familien mit niedrigerem Einkommen, die drei Monate oder länger arbeitslos waren, würden Vorrang für die Unterstützung erhalten. Weiterlesen.

In offensichtlicher Erwartung der Ankündigung vom Mittwoch gab die FDA am Dienstag bekannt, dass sie neue Empfehlungen und Informationen für Testentwickler bereitstellt, um den Weg zur Notfallgenehmigung für Screening-Tests zu „rationalisieren“.

Dr. Mina sagte jedoch, dass die neuen Richtlinien nicht das ansprechen, was er als grundlegendes Problem ansieht: Die FDA hält die Zulassung neuer Antigen-Schnelltests, einschließlich Tests zu Hause, auf, indem sie diese falsch an den empfindlicheren PCR-Tests messen. Dr. Mina sagte, die beiden seien nicht vergleichbar. Während Schnelltests verfügbar sind, ist ihre Produktion weit hinter dem Bedarf zurückgeblieben. Derzeit sind nur drei Tests zu Hause von der FDA zugelassen.

“Die Anforderungen der FDA haben nicht mit der Wissenschaft Schritt gehalten”, sagte er. “Sie leben in dieser archaischen Welt, in der PCR der einzige Test und die einzige Metrik ist und buchstäblich einen Antigen-Test nach dem Antigen-Test erfordert, um im Fegefeuer begraben zu werden.”

Er wies auch darauf hin, dass die Richtlinien des Bundes keine andere Hürde für Schulen darstellen: die Anforderung, dass sie eine Zertifizierung gemäß den Clinical Laboratory Improvement Amendments (CLIA) erhalten müssen, einer Reihe von Vorschriften von 1988, die Beschränkungen für die Durchführung von Labortests auferlegen.

Dr. Walensky sagte am Mittwoch, dass einige Staaten zwar kreative Wege gefunden haben, um die Anforderung zu umgehen, „aber noch mehr Arbeit zu tun ist“, um das Problem anzugehen.

Die 2,25 Milliarden US-Dollar für Tests in unterversorgten Bevölkerungsgruppen sollen die durch die Pandemie aufgedeckten Rassenunterschiede beseitigen. Schwarze und Latinos infizieren sich weitaus häufiger mit dem Coronavirus als Weiße und sterben an Covid-19. Diese Unterschiede erstrecken sich laut Experten auf Tests. Die Impfrate für Schwarze in den Vereinigten Staaten ist halb so hoch wie für Weiße, und die Kluft für Hispano-Amerikaner ist laut einer Times-Analyse staatlich gemeldeter Informationen zu Rasse und ethnischer Zugehörigkeit sogar noch größer.

Das Geld wird in Form von Zuschüssen an öffentliche Gesundheitsbehörden vergeben, um deren Fähigkeit zu verbessern, das Virus zu testen und zu verfolgen.

Dr. Marcella Nunez-Smith, Leiterin der Covid-19-Equity-Task Force von Herrn Biden, sagte Reportern, dass die Verwaltung auch daran arbeite, Therapiebehandlungen, einschließlich monoklonaler Antikörpertherapien, mit einem Zuschuss von 150 Millionen US-Dollar an unterversorgte Gemeinden zu bringen.

“Für diejenigen Personen, die Covid-19 erhalten, möchten wir sicherstellen, dass auch sie von den neuesten wissenschaftlichen Erkenntnissen profitieren”, sagte sie, “um ihnen zu helfen, zu hoffen und ihnen zu einer sicheren und schnellen Genesung zu verhelfen.”

Emily Anthes trug zur Berichterstattung aus New York bei.